AfternsAfterns
Up or down this time?Jan 26 scheduled
0%0%

···

Johnson & Johnson (JNJ) earnings date & stock reaction

Johnson & Johnson · Healthcare

ReportedOct 13EPS $2.59(est $2.52)+2.7% beat· Rev $25.4B
“In Q3, we reported operational sales growth of 6% ahead of analyst consensus and increased sequential growth compared to the second quarter.”
· Joaquin Duato, CEO
“We now expect full-year operational sales growth in the range of 6.7%-7.1%, which represents operational sales of $100.7 billion at the midpoint.”
· Joe Wolk, CFO
Positives
  • ▲Robust growth in Innovative Medicine
    • Innovative Medicine revenue reached $16.8 billion this quarter, up 7.9% vs last year.
    • TREMFYA sales surged 68.2% YoY, driving momentum in the immunology segment.
  • ▲Upward revision of annual guidance
    • Reflecting strong performance, the full-year revenue guidance midpoint was raised to $101.2 billion.
    • Adjusted EPS guidance midpoint was increased by $0.06 to $11.10.
  • ▲Expansion of oncology portfolio
    • The oncology business grew approximately 17% this quarter, supporting overall results.
    • RYBREVANT sales increased 63.5% YoY, strengthening its position in lung cancer treatment.
Concerns
  • ▼Slowdown and weakness in MedTech
    • MedTech revenue grew only 2.5% to $8.6 billion, falling short of internal expectations.
    • Abiomed revenue declined 1.5% YoY due to lower patient volumes.
  • ▼Margin compression and rising costs
    • Adjusted operating margin for the enterprise fell to 30.2% from 35.2% last year.
    • Cost of goods sold deleveraged by 150 basis points due to unfavorable product mix and amortization.
  • ▼Regional decline in Surgery segment
    • Surgery revenue declined 1% YoY, impacted by VBP expansion in China and disruptions in the Middle East.
Based on the Oct 13, 2026 earnings-call transcript. Quotes are verbatim.
Next earningsTue, January 26 around 8:00 AM ET, before the openscheduled

Price after the latest report

Reported October 13, 2026how the stock moved around it
Next-day move
-5.5%
Price around earnings
Around this report
Overlapped CPI releaseA major data release (CPI, jobs) came out around this report. On those days the whole market moves, so the reaction may be mixed with the data.

Johnson & Johnson (JNJ) rose the day after earnings in 9 of its last 12 reports (75%), moving ±2.2% on average. It has fallen despite beating the consensus estimate 3 times.

Up next day
9/12
75%
Fell despite growth
1/12
Good earnings ignored
Price when beating
+1.1%
avg over 11 beats
Price when missing
—
never missed
Avg earnings move
±2.2%
typical swing on earnings
Biggest single move
+6.2%
'25.7 · largest reaction
🔑What actually moves this stock?
What really matters here
Blockbuster drug sales and the company's next-year outlook
In finance terms: Key drug sales · guidance
Growth · revenue (YoY by quarter, latest right)
+6%
25-07(Jun qtr)
+7%
25-10(Sep qtr)
+9%
26-02(Dec qtr)
+10%
26-04(Mar qtr)
+7%
26-07(Jun qtr)
+6%
26-10(Sep qtr)
Holding steady · Growth is holding around +6%.
What to watch next report

When results drop, skip the EPS number. Check if the growth above holds or accelerates, and whether guidance beats expectations.

The real bar for this stock

Beating estimates isn't enough. Here's where the real surprise started.

Beat consensus 11 of 12 times. Beating is the default here
Median beat +2.3%. 3 of those beats still fell the next day.
Reports that rose beat by +3.2% (median). Reports that fell beat by just +1.5%
Roughly +3.2% was the bar this stock had to clear.

How this stock reacts to earnings

Traits seen across its recent earnings reactions

Good results usually push the stock up
Up the next day 8 of 11 beats (73%)
Big earnings-day moves tend to fade within days
Reversed the day-one move · 73% of last 11
vs Healthcare sector avg (155 peers)
This
+1.1%
Sector
+0.5%
Avg next-day reaction

Earnings number vs guidance: which drives it?

How often the beat/miss matched the actual price move

This stock mostly moves with the reported earnings number
Moved opposite to results 3 of last 11 times (27%)
3xBeat but fell
Even a beat sells off if guidance disappoints
0xMissed but rose
Even a miss rebounds if guidance reassures
Fell despite growth1/12

3/11 beats fell next day · watches Key drug sales · guidance

Next-day reaction
  • Sep 2026 report-5.5%
  • Jun 2026 report+0.3%
  • Mar 2026 report+1.1%
  • Dec 2025 report+1.1%
  • Sep 2025 report-0.0%
  • Jun 2025 report+6.2%

Earnings timeline · bars = next-day move, ▲▼ = beat/miss

Jul–Sep 2026 results
Reported 2026-10-13
Next-day move
-5.5%
After 5 days —
EPS consensus $2.52 → $2.59 ▲ +2.7% beatRev $24.0B → $25.4B +6% YoY
Beat by +2.7% but stock -5.5%
Price around earnings
Around this report
Overlapped CPI releaseA major data release (CPI, jobs) came out around this report. On those days the whole market moves, so the reaction may be mixed with the data.

Earnings trend · last 12 quarters

EPS$2.59YoY -8%
'24.2'26.10
Revenue$25.4BYoY +6%
'24.2'26.10

Earnings history and price reaction

Johnson & Johnson across its last 12 earnings reports: EPS versus consensus, the move on the earnings day, and the cumulative move five trading days later.
Quarter endedReported (ET)vs market expectation (consensus)Earnings dayAfter 5 days
9/20262026-10-13+2.7%-5.5%—
6/20262026-07-28+1.6%+0.3%-4.3%
3/20262026-04-28+0.8%+1.1%-0.5%
12/20252026-02-11-0.1%+1.1%+2.8%
9/20252025-10-14+1.5%-0.0%+1.5%
6/20252025-07-16+3.2%+6.2%+8.2%

12 reports, quarters ending 12/2023 to 9/2026. The earnings-day move is the first trading day that reflects the report; the five-day figure is the cumulative move from that point.

Frequently asked questions

When is the next Johnson & Johnson earnings date?

The next Johnson & Johnson (JNJ) earnings report is expected Tue, January 26 around 8:00 AM ET, before the open. It comes from an earnings calendar and may not be a company-confirmed date; it updates automatically if it changes.

Does Johnson & Johnson (JNJ) stock usually go up after earnings?

Over the last 12 earnings reports, the stock rose on 9 of them (75%). The average move on earnings day was ±2.2%.

Does Johnson & Johnson react more to the earnings numbers or to guidance?

In 3 of the last 11 reports (27%), the stock moved the opposite way from whether it beat or missed the forecast. A high share means guidance and expectations drive the move more than the reported numbers.

Can Johnson & Johnson stock fall even when earnings are good?

Yes. In 1 of the last 12 reports, Johnson & Johnson fell on the earnings day despite growing EPS. Expectations already priced in, or guidance, can matter more than the reported numbers.

Does Johnson & Johnson stock keep moving after the earnings day?

Over the last 11 reports, the move continued in the same direction for the following five trading days 27% of the time. This tendency is known as post-earnings announcement drift.